Non-clinical ICH/FDA guidances relate to safety studies

  1. What major non-clinical ICH/FDA guidances relate to safety studies for the conduct of human clinical trials (in addition to M3R2)?
  2. What studies must be conducted in the nonclinical safety assessment for human clinical trials? Very briefly describe the purpose of each of the studies.
  3. What additional nonclinical studies may be required to assess studies on a case-by-case basis?
  4. Which R&D and Operations departments/functions are typically not subject to the Good Laboratory Practice regulations (excluding those covered by Good Manufacturing Practices)?
  5. What is the definition of toxicokinetic studies and what is their purpose?
  6. What is the primary purpose of non-clinical research and development?
  7. When planning long-term carcinogenicity studies in rodents for a new drug product, what are the factors that should be considered?
  8. In what situations, if any, might a drug product receive marketing approval before required carcinogenicity testing is conducted or completed?
  9. When conducting drug product stability testing, what drug product attributes should be tested?